Pirfenidone exerts a suppressive effect on CCL18 expression in U937-derived macrophages partly by inhibiting STAT6 phosphorylation
- 27 October 2016
- journal article
- research article
- Published by Taylor & Francis in Immunopharmacology and Immunotoxicology
- Vol. 38 (6) , 464-471
Abstract
Context: CC chemokine ligand 18 (CCL18) is suggested to play a role in the development of pulmonary fibrosis. Macrophages are thought to be the main source of CCL18, and the effect of pirfenidone, an anti-fibrotic agent for idiopathic pulmonary fibrosis, on the expression of CCL18 in macrophages warrants investigation. Objective: The purpose of this study was to investigate the effect of pirfenidone on the expression of CCL18 in macrophages. Materials and methods: U937 cells were differentiated into macrophages by phorbol myristate acetate and then stimulated with recombinant IL-4 to induce the production of CCL18. The cells were treated with pirfenidone, and the mRNA and protein levels for CCL18 were measured by a reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. The effects of pirfenidone on the IL-4 receptor (IL-4R) expression and STAT6 activation were investigated and on the JAK kinase activity were measured using the Z′-LYTE™ kinase assay. Results: Pirfenidone significantly suppressed the expression of CCL18 when the cells were treated with concentrations of 50–250 μg/mL. Pirfenidone did not affect the expression of the IL-4R components. The selective STAT6 inhibitor AS1517499 suppressed CCL18 expression. Both AS1517499 and pirfenidone suppressed STAT6 phosphorylation (p < .05), although the effect of pirfenidone was less marked than that of AS1517499. The Z′-LYTE™ kinase assay showed a reduction in the activities of JAK1, JAK3 and TYK2 by pirfenidone. Conclusion: Pirfenidone suppresses CCL18 expression in macrophages and this effect is thought to be attributed partly to the inhibition of STAT6 phosphorylation.Keywords
This publication has 39 references indexed in Scilit:
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- Pirfenidone in idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2009
- Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosisEuropean Journal of Pharmacology, 2008
- Incidence and Prevalence of Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Pirfenidone effectively reverses experimental liver fibrosisJournal of Hepatology, 2002
- Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA‐salt hypertensive ratsBritish Journal of Pharmacology, 2002
- Pirfenidone Inhibits Dimethylnitrosamine‐Induced Hepatic Fibrosis In RatsClinical and Experimental Pharmacology and Physiology, 2001
- Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin‐diabetic ratsBritish Journal of Pharmacology, 2001
- Pirfenidone improves renal function and fibrosis in the post-obstructed kidneyKidney International, 1998